http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-108721261-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-704 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-11 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-11 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-704 |
| filingDate | 2018-09-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2020-09-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2020-09-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-108721261-B |
| titleOfInvention | Application of erythrina glycoside A1 or erythrina glycoside A2 in preparing medicine for treating breast cancer |
| abstract | The invention discloses application of erythrina glycoside A1 or erythrina glycoside A2 in treating breast cancer. The invention discovers that the macrocarpal B and the erythrina glycoside A1 have obvious proliferation inhibition effect on human colon cancer; the macrocarpal C and the erythrina glycoside A1 have obvious proliferation inhibition effect on human liver cancer; the macrocarpal B, the macrocarpal C, the erythrina glycoside A1 and the erythrina glycoside A2 have no obvious proliferation inhibition effect on human lung adenocarcinoma, but have obvious proliferation inhibition effect on human breast carcinoma. This may be related to the parent nucleus of the chemical structure and the substituent species. |
| priorityDate | 2018-09-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 22.